Literature DB >> 24625462

PharmGKB summary: abacavir pathway.

Julia M Barbarino1, Deanna L Kroetz, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24625462      PMCID： PMC4074515          DOI： 10.1097/FPC.0000000000000040

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  51 in total

1.  Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.

Authors:  L Escaut; J Y Liotier; E Albengres; N Cheminot; D Vittecoq
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

Authors:  Firouzé Bani-Sadr; Lise Denoeud; Patrice Morand; Françoise Lunel-Fabiani; Stanislas Pol; Patrice Cacoub; Christian Perronne; Fabrice Carrat
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

Review 3.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  T N Kakuda
Journal:  Clin Ther       Date:  2000-06       Impact factor: 3.393

4.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

5.  Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Authors:  Dyfrig A Hughes; F Javier Vilar; Charlotte C Ward; Ana Alfirevic; B Kevin Park; Munir Pirmohamed
Journal:  Pharmacogenetics       Date:  2004-06

6.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Authors:  Michael Saag; Rukmini Balu; Elizabeth Phillips; Philip Brachman; Claudia Martorell; William Burman; Britt Stancil; Michael Mosteller; Cindy Brothers; Paul Wannamaker; Arlene Hughes; Denise Sutherland-Phillips; Simon Mallal; Mark Shaefer
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

7.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

Authors:  Diana Chessman; Lyudmila Kostenko; Tessa Lethborg; Anthony W Purcell; Nicholas A Williamson; Zhenjun Chen; Lars Kjer-Nielsen; Nicole A Mifsud; Brian D Tait; Rhonda Holdsworth; Coral Ann Almeida; David Nolan; Whitney A Macdonald; Julia K Archbold; Anthony D Kellerher; Debbie Marriott; Simon Mallal; Mandvi Bharadwaj; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

8.  Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.

Authors:  J A McDowell; G E Chittick; J R Ravitch; R E Polk; T M Kerkering; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

9.  HLA-B*5701 testing to predict abacavir hypersensitivity.

Authors:  Joseph D Ma; Kelly C Lee; Grace M Kuo
Journal:  PLoS Curr       Date:  2010-12-07

10.  The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods.

Authors:  Laura Stocchi; Raffaella Cascella; Stefania Zampatti; Antonella Pirazzoli; Giuseppe Novelli; Emiliano Giardina
Journal:  Curr Genomics       Date:  2012-06       Impact factor: 2.236
View more
  6 in total

1.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

2.  Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women.

Authors:  C L Pearce; D Stram; A Wiensch; M A Frasco; N Kono; D V Den Berg; K Anastos; M H Cohen; J DeHovitz; E T Golub; B Tamraz; C Liu; W J Mack
Journal:  Int J HIV AIDS Res       Date:  2017-09-05

3.  Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?

Authors:  Víctor Collado-Díaz; Maria Ángeles Martinez-Cuesta; Maria Amparo Blanch-Ruiz; Ainhoa Sánchez-López; Patricia García-Martínez; José E Peris; Iris Usach; Maria Dolores Ivorra; Alessandra Lacetera; Sonsoles Martín-Santamaría; Juan V Esplugues; Angeles Alvarez
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

4.  Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K-specific inhibition.

Authors:  Eric T Baldwin; Matthias Götte; Egor P Tchesnokov; Eddy Arnold; Margit Hagel; Charles Nichols; Pam Dossang; Marieke Lamers; Paul Wan; Stefan Steinbacher; Donna L Romero
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-30       Impact factor: 12.779

Review 5.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820

Review 6.  PharmGKB: A worldwide resource for pharmacogenomic information.

Authors:  Julia M Barbarino; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2018-02-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.